Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1–5 years with iatrogenic chronic hepatitis C

Hepatology International

Volumn 9, Issue 4, 2015, Pages 578-585

  Zhu, Shi Shu ^a   Zeng, Qing Lei ^a,b   Dong, Yi ^a   Xu, Zhi Qiang ^a   Wang, Li Min ^a   Chen, Da Wei ^a   Gan, Yu ^a   Wang, Fu Chuan ^a   Yan, Jian Guo ^a   Cao, Li Li ^a   Wang, Pu ^a   Han, Jin ^a   Zhang, Xue Xiu ^a   Zhang, Zheng ^a   Zhang, Hong Fei ^a   Wang, Fu Sheng ^a  

^a BEIJING 302 HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Antiviral therapy; Children; Epidemiology; Hepatitis C virus; Iatrogenic infection

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA1 INTERFERON; ALPHA1B INTERFERON; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; VIRUS RNA;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATURIA; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1B; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 2A; HUMAN; HYPOTHYROIDISM; INJECTION SITE REACTION; LIVER FIBROSIS; MACROHEMATURIA; MAJOR CLINICAL STUDY; MALE; PANCYTOPENIA; PRIORITY JOURNAL; PRURITUS; RASH; SLEEP DISORDER; THYROTOXICOSIS; ADOLESCENT; BIOPSY; CHINA; COMBINATION DRUG THERAPY; DOSE RESPONSE; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; IATROGENIC DISEASE; INCIDENCE; INFANT; LIVER; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; BIOPSY; CHILD; CHILD, PRESCHOOL; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IATROGENIC DISEASE; INCIDENCE; INFANT; INTERFERON-ALPHA; LIVER; MALE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84944450854     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-015-9671-8     Document Type: Article

References (25)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–714
2. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012;54:838–855
3. Porto AF, Tormey L, Lim JK. Management of chronic hepatitis C infection in children. Curr Opin Pediatr 2012;24:113–120
4. European Association for Study of Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245–264
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374
6. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556–562
7. Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009;4:e8467
8. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372–374
9. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866–870
10. Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J 2011;30:983–985
11. Rosen HR. Chronic hepatitis C infection. N Engl J Med 2011;364:2429–2438
12. Delgado-Borrego A. Treating hepatitis C: are children the same as adults? Gastroenterology 2011;140:389–392
13. Robinson JL, Doucette K. The natural history of hepatitis C virus infection acquired during childhood. Liver Int 2012;32:258–270
14. Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275–280
15. Iorio R, Giannattasio A, Sepe A, Terracciano LM, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005;41:1431–1437
16. Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900–1907
17. Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005;42:1010–1018
18. Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450–458
19. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501–507
20. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401
21. Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006;148:353–358
22. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34–44
23. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med 2014;370:1869–1871
24. Chung RT, Baumert TF. Curing chronic hepatitis C—the arc of a medical triumph. N Engl J Med 2014;370:1576–1578
25. Liang TJ, Ghany MG. Therapy of hepatitis C—back to the future. N Engl J Med 2014;370:2043–2047